Tag: Viaskin® Peanut

Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Neffy Intranasal Epinephrine Device

CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...

The market for epinephrine delivery may expand to include non-needle alternatives next year.
Viaskin Patch

Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...

The patch therapy remains in regulatory limbo.
Viaskin-Patch

Safety of Viaskin Peanut Patch Therapy Improved Over 3-Year Study

Reactions decreased over study duration.
Viaskin Peanut

FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays

Delays mount pushing trials of modified patch.
Moonlight Therapeutics Microneedle Patch

New Microneedle Patch Therapy for Food Allergies Takes Step Forward

Painless microneedle patch may provide new method for desensitization.
Viaskin Patch

DBV Optimistic Viaskin Peanut “Patch” Therapy has Path to Approval After...

DBV, which also has Viaskin therapies for milk and egg allergies in their pipeline, is encouraged by FDA feedback after denial of their peanut therapy.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...

The company announced they would be laying off 200 employees in Q1.
Viaskin Patch

Viaskin Peanut “Patch” Therapy Takes Next Step Toward Approval… in Europe

The Marketing Authorization Application for Viaskin™ Peanut was validated by the European Medicines Agency.
Viaskin Peanut

FDA Denies Approval of Viaskin Peanut “Patch” Therapy

The FDA raised concerns that adhesion of the patch would affect the efficacy of the therapy.